A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of Sandostatin® LAR® and pegvisomant, in acromegalic patients only partially responsive to somatostatin analog monotherapy - PHOENIX

ovartis Pharma GmbH0 个研究点目标入组 100 人开始时间: 2006年6月20日最近更新: 2012年12月10日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 100

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Male or female patients aged 18 years or older.
•2.Patients with prior surgery of micro- or macroadenoma of the pituitary.
•3.At least 6 months chronic treatment with somatostatin analogues abd the last 3 months treated with the highest dose of somatostatin analogues.
•5.Lack of suppression of GH nadir to < 1.0 mcg/l, after oral administration of 75 g of glucose (OGTT) and IGF-I levels at least 10% above the normal value ± 2 SD must be proven within 4 weeks prior to visit 1.
•However, if acromegaly symptoms are inadequately controlled as defined in the acromegaly comorbidities and symptom evaluation (as judged by the investigator), an abnormal GH or IGF-1-value as defined above is sufficient.
•6.Patient’s written informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1.Requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass.
•2.Radiotherapy planned or radiotherapy for acromegaly within the last 2 years.
•3.Symptomatic cholelithiasis that is clinically relevant.
•4.Psychose in anamnesis.
•5.Severe cardiovascular dysfunction (for example cardiomyopathy, congestive heart failure NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, fibrosis of heart valvila and lung.
•6.Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis, or persistent ALT, AST, alkaline phosphatase 2 x > upper limit of normal, or total bilirubin 1.5 x > upper limit of normal.
•7. Any medical conditions contraindicated in the SPC of all study drugs.
•8.Abnormal clinical laboratory values considered by the Investigator to be clinically significant and which could affect the interpretation of the study results.
•9.Any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator.
•10. Patients with a complete resistence to somatostatin analogues therapy.
•11.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml).
•12. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or are using one or more of the following acceptable methods of contraception: surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation.
•13. Receiving treatment with dopamine agonists within the last 6 months.
•14. Prior treatment with GH-receptor-antagonists.
•15. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half lives of enrollment, whichever is longer.
•16. History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures.
•17. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.
•18. Unable to complete the entire study for any reason.

研究者

发起方

ovartis Pharma GmbH

相似试验

进行中（未招募）

不适用

A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonates - ND

EUCTR2009-009756-21-ITAmgen Inc33

进行中（未招募）

不适用

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumHypercalcemia of malignancy (HCM)MedDRA version: 15.0Level: LLTClassification code 10020588Term: Hypercalcemia of malignancySystem Organ Class: 10014698 - Endocrine disorders

EUCTR2009-009756-21-PLAmgen Inc33

进行中（未招募）

1 期

EUCTR2009-009756-21-FRAmgen Inc33

尚未招募

4 期

To evaluate the safety and performance of Dafodil™ Pericardial Bioprosthesis in patients undergoing native/prosthetic aortic or mitral valve replacement.

CTRI/2024/04/064961Meril Diagnostics private Limited

尚未招募

不适用

A prospective, single-arm, multicenter, investigator-initiated, interventional study to evaluate the efficacy and safety of switching from low- and moderate-intensity statin to Ezetimibe 10 mg and ROsuvastatIn 2.5 mg CombinAtion therapy in patients with type 2 diabetes mellitus with dyslipidemia. (EROICA)

KCT0008224Hanyang University Guri Hospital665